Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2009

Ocera Licenses Acute Hepatic Encephalopathy Preclinical Treatment from UCLB

  • Ocera Therapeutics purchased rights to University College London Business’ (UCLB) assets and technologies related to a compound for the treatment of acute hepatic encephalopathy (AHE). The company will develop it as its second pipeline compound and refer to it as OCR-002.

    OCR-002 will be investigated as an injectable treatment of AHE in patients with advanced liver cirrhosis and acute liver failure. Clinical trials in patients with AHE due to cirrhosis and acute liver failure will be carried out at University College Hospital as well as other centers in 2009 under funding from the Medical Research Council in the U.K. Ocera is planning to file an IND in late 2009, and U.S. trials will begin in early 2010.

    Research at the University College London demonstrated an acute and sustained reduction of systemic ammonia levels as well as decreased intracranial pressure in models of AHE in acute liver failure and cirrhosis.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »